The therapeutic success of imatinib in chronic myeloid leukemia (CML) is hampered by persistence of malignant stem cells. We investigated whether nilotinib, a more potent BCR-ABL kinase inhibitor could target CML primitive progenitors more effectively than imatinib. CML and normal progenitor cells were cultured with nilotinib or imatinib in growth factor supplemented medium. Nilotinib inhibited BCR-ABL kinase activity at lower concentrations than imatinib. Nilotinib inhibited mitogen-activated protein kinase (MAPK), AKT and STAT5 phosphorylation in CML CD34
Introduction
Chronic myeloid leukemia (CML) is a malignant hematopoietic disorder that is characterized by the Philadelphia chromosome (Ph), resulting from a reciprocal translocation between the long arms of chromosomes 9 and 22. At the molecular level, N-terminal sequences of the BCR gene on chromosome 22 fuse to c-ABL sequences on chromosome 9. The BCR-ABL fusion gene represents the pathogenetic hallmark of the disease and encodes a protein with elevated, deregulated tyrosine kinase (TK) activity. BCR-ABL expression results in increased proliferation, reduced apoptosis and disturbed interaction with the extracellular matrix in the malignant clone, leading to abnormal expansion of myeloid progenitors and more differentiated cells. 1 Imatinib mesylate (imatinib), a small-molecule BCR-ABL TK inhibitor, has proven to be active in all phases of Ph þ CML. [2] [3] [4] Durable cytogenetic remissions are achieved in the majority of patients with early-phase disease. 5, 6 However resistance may occur, particularly in patients with advanced-phase disease, and has been related to mutations in the ABL kinase domain, overexpression of BCR-ABL due to genomic amplification or acquisition of additional genetic abnormalities. 7 There is evidence that primitive Ph þ progenitor cells are relatively resistant to elimination by imatinib. [8] [9] [10] Residual malignant progenitors are found in patients who achieve cytogenetic response with imatinib treatment. 11 Our previous studies suggest that imatinib suppresses CML progenitor growth primarily through suppression of abnormally increased proliferation, but results in only modest increase in apoptosis. 8 Nondividing primitive progenitors are insensitive to imatinib-induced apoptosis. 10 Mathematical modeling of Q-PCR data also suggest that imatinib inhibits production of differentiated leukemia cells, but does not deplete leukemia stem cells. 12 Since leukemia stem cells may represent a source of disease maintenance, targeting and elimination of these cells may be required for the achievement of long-term remission in a greater proportion of patients.
Nilotinib (AMN107) is a novel, highly selective BCR-ABL TK inhibitor that is being evaluated in clinical trials for treatment of CML patients who fail imatinib therapy. 13 Nilotinib exerts 30-fold more activity against the BCR-ABL kinase compared with imatinib, and can inhibit most clinically relevant imatinibresistant mutants. [14] [15] [16] Since incomplete inhibition of BCR-ABL TK activity in CML progenitors is a potential mechanism underlying their incomplete elimination, it is of interest to examine whether a more potent TK inhibitor could result in enhanced targeting of malignant primitive leukemia progenitors. In this study, we investigated the effects of nilotinib on BCR-ABL TK activity, as well as on downstream targets of BCR-ABL in CML CD34 þ cells. We examined the effect of nilotinib on the growth of CML primitive and committed progenitor cells in colony-forming cell (CFC) and long-term culture-initiating cell (LTC-IC) assays, to inhibit primitive and committed progenitor proliferation, to induce apoptosis and to target undivided cells. To address the possibility of 'off-target' effects unrelated to inhibition of BCR-ABL kinase activity, comparison with normal progenitor cells was performed.
Patients, materials and methods

Subjects
Peripheral blood samples from newly diagnosed, untreated chronic-phase CML patients and umbilical cord blood samples from healthy donors were obtained under guidelines approved by the Institutional Review Board of the City of Hope National Medical Center (Duarte, CA, USA).
Inhibitors
Imatinib and nilotinib were provided by Novartis Pharmaceuticals (East Hanover, NJ, USA). A 10-mM stock solution of both drugs was prepared in dimethylsulfoxide and stored at À20 1C.
Selection of CD34 þ progenitors
Mononuclear cells were isolated by Ficoll-Hypaque (Sigma Diagnostics, St Louis, MO, USA) density-gradient centrifugation (specific gravity, 1.077) for 30 min at 400 g. CD34 þ cells were selected by means of immunomagnetic column separation (Miltenyi Biotech, Auburn, CA, USA) following the manufacturer's instructions.
Cell culture and exposure to inhibitors CD34 þ cells were cultured in tissue-culture plates (Falcon; BD Biosciences, Bedford, MA, USA) at 37 1C in a humidified atmosphere with 5% CO 2 , in serum-free medium (StemCell Technologies, Vancouver, British Columbia, Canada) supplemented with growth factors (GFs) at concentration similar to that found in stroma-conditioned medium from long-term bone marrow cultures (200 pg ml À1 granulocyte-macrophage colonystimulating factor; 1 ng ml À1 granulocyte colony-stimulating factor; 200 pg ml À1 stem cell factor; 50 pg ml À1 leukemia inhibitory factor; 200 pg ml À1 macrophage-inflammatory protein-1a and 1 ng ml À1 interleukin 6; hereafter called 'low GF').
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Nilotinib or imatinib was added at the indicated concentrations. Cells were harvested after 96 h and assayed for progenitor growth and proliferation and apoptosis, as described previously.
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Progenitor assays: colony-forming cells CD34 þ cells were cultured for 96 h in the presence or absence of inhibitors. Cells were plated in methylcellulose progenitor culture and burst-forming unit-erythroid and colony-forming unit-granulocyte and macrophage were counted after 14 days.
Long-term culture-initiating cells
Cells were plated in long-term bone marrow culture medium on M2-10B4 murine fibroblast feeders subcultured in 96-well plates. Cultures were maintained at 37 1C in a humidified atmosphere with 5% CO 2 , and fed at weekly intervals. After 6 weeks, wells were overlaid with CFC growth-supporting medium. After 2 weeks, wells were scored as positive or negative for the presence of CFCs. The frequency of LTC-ICs was calculated with L-Calc software (StemCell Technologies).
Apoptosis assay
CD34 þ CD38 þ and CD34 þ CD38À progenitor cells were cultured for 96 h in the presence or absence of inhibitors, labeled with Annexin V-Phycoerythrin (BD Pharmingen, San Diego, CA, USA) according to the manufacturer's instruction, and analyzed by flow cytometry. Apoptotic cells were defined as Annexin V-Phycoerythrin þ .
Proliferation assay
A 5-(and 6-)carboxyfluorescein diacetate succinimidyl ester-(Molecular Probes, Eugene, OR, USA) labeling assay was performed as described previously. 
Statistical analysis
Data obtained from independent experiments on multiple patient samples were reported as the mean ± s.e.m. Significance levels were determined by Student's t-test analysis.
Results
Effects of nilotinib on BCR-ABL kinase activity
To assess the effects of nilotinib and imatinib on BCR-ABL TK activity, CML CD34 þ cells were separately exposed to nilotinib (0-10 mM) and imatinib (0-5 mM) as single agents in low-GF conditions for 16 h, and western blotting was performed to detect CRKL phosphorylation. Phosphorylated CRKL (P-CRKL) was distinguishable from non-phosphorylated CRKL by its slower migration. The CRKL phosphorylation assay has been validated as a practical method for evaluating inhibition of BCR-ABL TK activity in primary CML cells. 18, 19 As shown in Figure 1a , P-CRKL protein levels were high in untreated controls and effectively suppressed after treatment with nilotinib for 16 h at doses as low as 0.25 mM. Increasing the nilotinib concentration to 5.0 mM resulted in further suppression of P-CRKL protein levels. Treatment with imatinib at 0.25 and 0.5 mM, however, resulted in only partial suppression of P-CRKL level. However, increasing the imatinib dose to the 1 mM range led to a reduction in P-CRKL levels similar to that achieved with nilotinib. We further demonstrate that low concentrations (0.5 mM) of nilotinib were also more effective than imatinib in inhibiting CRKL phosphorylation in CD34 þ CD38À cells, whereas higher concentrations of nilotinib and imatinib (5 mM) were similarly effective in inhibiting CRKL phosphorylation in this sub-population (Figure 1b) .
Effect of nilotinib treatment on CML LTC-IC-and CFC-growth
Chronic myeloid leukemia and normal CD34 þ cells were exposed to nilotinib and imatinib as single agents for 96 h under low-GF conditions. The effects of nilotinib and imatinib were tested pairwise on cells from the same patients. Following drug exposure, assays for primitive (LTC-IC) and committed (CFC) progenitors were performed. Normal progenitor cells were studied as controls to detect selectivity of inhibitor effects and detect 'off-target' effects. Exposure to nilotinib resulted in a dose-dependent inhibition of CML LTC-IC compared to untreated cells (Figure 2a) . Comparable effects were observed with imatinib treatment (Figure 2b ). In contrast, normal LTC-ICs were not significantly suppressed at doses below 10 mM of nilotinib and below 5 mM of imatinib (Figures 2a and b) . Nilotinib and imatinib both resulted in a dose-dependent suppression of CML CFCs (Figures 2c and d) . Differences between the two agents were not statistically significant. Normal CFCs showed less growth inhibition with nilotinib and imatinib. Cells in colonies generated from CD34 þ cells cultured without addition of drug were found to be 93.6% BCR-ABL positive by fluorescence in situ hybridization analysis. The residual CFCs remaining after nilotinib or imatinib treatment were also predominantly BCR-ABL positive (0.5 mM nilotinib: 89.5% BCR-ABL þ ; 0.5 mM imatinib: 92.5% BCR-ABL þ ). Therefore, incomplete inhibition of progenitor growth by nilotinib is not explained by selective persistence of BCR-ABL-negative cells. This is consistent with our previous observations that retention of PhÀ cells was not responsible for the lack of effect of imatinib on CML progenitors, 8 and in line with the findings described by other investigators. 20 Effect of nilotinib treatment on apoptosis and cell division of CML primitive and committed progenitors Carboxyfluorescein diacetate succinimidyl ester-labeled CD34 þ 38À and CD34 þ 38 þ cells were incubated with nilotinib and imatinib under low-GF conditions for 96 h, labeled with Annexin V-Phycoerythrin and analyzed by flow cytometry. As shown in Figure 3a , treatment of CML primitive progenitors with nilotinib resulted in a dose-responsive increase in apoptosis. Apoptosis was similarly increased in CML primitive (Figure 3b ). Treatment with 1 mM nilotinib or imatinib did not result in significant increase in apoptosis of normal primitive progenitors, whereas maximum doses of nilotinib (10 mM) and 5 mM imatinib resulted in modest increase in apoptosis (data not shown). We analyzed the proliferation of CML and normal progenitors by tracking cell division of carboxyfluorescein diacetate succinimidyl esterlabeled cells and generating a proliferation index using ModFit software. Untreated CML primitive and committed progenitors were significantly more proliferative compared with the corresponding normal population (data not shown). Treatment with nilotinib and imatinib resulted in similar significant, dose-responsive reduction in proliferation of CML CD34 þ CD38À primitive and CD34 þ CD38 þ committed progenitors (Figures 3c-f) . In contrast, the proliferation of normal progenitor cells was significantly reduced only at the highest concentrations of imatinib, and was not significantly reduced in response to nilotinib treatment (data not shown). We and others have shown that nondividing CML progenitors are relatively resistant to imatinib treatment. 9, 11 These primitive nondividing CML cells are Ph þ and express BCR-ABL. 10 As shown in Figure 3g , an increased proportion of undivided progenitors were seen after nilotinib treatment compared with untreated controls, similar to the proportion of undivided progenitors seen after imatinib treatment. Our results indicate that nilotinib suppresses CML primitive and committed progenitors by inhibition of proliferation, and to a lesser extent by inducing apoptosis. The presence or absence of stem cell factor in the low-GF mix did not alter progenitor inhibition by nilotinib and imatinib in CFCs, proliferation and apoptosis assays (data not shown).
Effects of nilotinib on downstream targets of BCR-ABL
We evaluated the effect of nilotinib on the MAPK-, PI-3K/AKTand STAT5-signaling pathways, which may be activated downstream of BCR-ABL and play a role in abnormal proliferation and survival of CML progenitors. Treatment of CML CD34 þ cells with nilotinib in the presence of low concentrations of GFs resulted in increased p42/44 MAPK activity compared with controls (Figure 4a ). These results are consistent with our previous observations that imatinib treatment of CML CD34 þ cells was associated with increased MAPK activity. 21 MAPK activity was increased to a greater extent in samples treated with 0.5 mM nilotinib compared with 0.5 mM imatinib (8.6-fold with nilotinib vs 3.5-fold with imatinib). However, 5 mM nilotinib or imatinib enhanced MAPK signaling to a similar extent (13.3-fold with nilotinib vs 22.7-fold with imatinib). In contrast, incubation of CD34 þ cells from healthy donors with the highest concentration of either imatinib or nilotinib did not enhance MAPK signaling (Figure 4b ). Incubation of CML CD34 þ cells with either nilotinib or imatinib, in the presence of GF, did not lead to a significant change in phospho-AKT and phospho-STAT5 levels (Figure 4a ). Since GF receptor engagement can induce signaling through the MAPK, PI-3K/AKT and STAT5 pathways, we also studied the effects of exposure of CD34 þ cells to nilotinib and imatinib in GF-free medium. Absence of GF was associated with reduced AKT and STAT5 activity in CML CD34 þ cells. Nilotinib and imatinib exposure in the absence of concomitant 
Nilotinib effects on CML stem cells H Konig et al
GF stimulation resulted in a significant decrease in MAPK, AKT and STAT5 phosphorylation (Figure 4c ). These results suggest that nilotinib and imatinib significantly inhibit BCR-ABLdependent activation of the MAPK, PI-3K and STAT5 pathways, but that these signaling pathways continue to be activated by exogenous GFs in nilotinib-or imatinib-treated cells. 
Discussion
Imatinib treatment induces cytogenetic remissions in the majority of CML patients in chronic phase, but patients in remission show persistence of residual leukemia cells, including malignant stem cells. 8, 9, 11 Incomplete inhibition of kinase activity in BCR-ABL þ CD34 þ cells by imatinib related to high BCR-ABL expression levels, impaired drug influx or increased efflux, or presence of kinase mutations that result in imatinib resistance, could contribute to incomplete elimination of malignant stem cells in imatinib-treated patients. 21, 22 Since nilotinib is a more potent inhibitor of the BCR-ABL kinase than imatinib, we investigated whether this compound could more effectively target primitive CML hematopoietic cells. Our results indicate that nilotinib is significantly more potent in inhibiting BCR-ABL TK activity in CML progenitor cells than imatinib. However, increased TK inhibitory activity did not translate into increased progenitor cell kill in vitro.
Nilotinib significantly suppressed BCR-ABL-positive primitive and committed progenitor cells derived from CML patients in chronic phase, in a dose-responsive manner. Nilotinib-induced suppression occurred at clinically achievable concentrations. Although the pharmacokinetic profile has not yet been fully established, plasma levels of nilotinib in excess of 10 mM were readily achieved in animal models and trough plasma levels of 2-5 mM were achieved in phase 1 and phase 2 clinical studies. 13, 15 We observed that nilotinib has similar activity in inhibiting CML LTC-ICs and CFCs, compared with imatinib. Exposure to the highest concentration of both drugs, such as could be achieved with therapeutic exposures, resulted in similar progenitor suppression, but did not completely eliminate malignant CFCs or LTC-ICs. Under the same conditions, progenitors from healthy donors were only suppressed at the highest inhibitor concentrations, with LTC-ICs being less sensitive than were CFCs. Increased sensitivity of CML, compared with normal progenitors, to nilotinib indicates a good therapeutic index similar to what has been previously reported for imatinib. 8, 23 Analyzing the mechanisms underlying growth suppression mechanisms, we observed that CML primitive and committed progenitor cell division was similarly inhibited by both drugs. We observed only a moderate increase in apoptosis in both CML primitive and committed progenitor cells following nilotinib exposure, and did not observe nilotinib to be more effective than imatinib in this respect. We have previously shown that nondividing CML progenitors are resistant to imatinibinduced apoptosis. In addition, the antiproliferative effects of imatinib likely also enhance numbers of nondividing progenitors. Our observation that nilotinib treatment did not significantly reduce the number of nondividing CML primitive progenitors is consistent with the similar antiproliferative and antiapoptotic effects of the two drugs. 9, 11 We used inhibition of CRKL phosphorylation as a surrogate assay to measure the effects of nilotinib and imatinib on BCR-ABL TK activity. Although the maximal inhibition of CRKL phosphorylation by nilotinib and imatinib was similar, nilotinib was significantly more potent in inhibiting CRKL phosphorylation in CML progenitor cells at lower drug concentrations than imatinib. Differences between these results and those previously reported by Jorgensen and co-workers, indicating equivalent inhibition of BCR-ABL TK activity by nilotinib and imatinib, may reflect higher sensitivity of detection of low degrees of kinase inhibition in the western blotting assay used here. Our observations indicate that adequate intracellular levels of drugs are achieved to effectively suppress BCR-ABL kinase activity in CML CD34 þ and CD34 þ CD38À cells. Therefore, the limited effects of nilotinib on progenitor viability do not appear to be attributable to lower intracellular drug levels secondary to reduced drug uptake or increased drug efflux. It has been reported that sole suppression of BCR-ABL activity is insufficient to eliminate BCR-ABL( þ ) KIT( þ )-expressing immature murine myeloid leukemic cells, and that therapeutic effectiveness of small-molecule drugs such as imatinib could be due to the inhibitor's ability to suppress other protein kinases in addition to the dominant target. 24 A need for inhibition of c-KIT kinase in addition to the BCR-ABL kinase to achieve growth inhibition of malignant stem cells could offer a possible explanation for why enhanced potency for BCR-ABL kinase inhibition by nilotinib does not lead to increased suppression of CML progenitor growth compared with imatinib, since nilotinib and imatinib have similar inhibitory effects on c-KIT. Downstream signaling mechanisms activated by the BCR-ABL TK in CML include the Ras/MAPK-, PI-3K/AKT-and STAT5-signaling pathways. 25, 26 Treatment of CML CD34 þ cells with nilotinib in the presence of GF was associated with increased p42/p44 MAPK signaling. These results are consistent with our previous studies with imatinib. 21 Greater enhancement of MAPK signaling was seen at low concentration of nilotinib compared with imatinib, consistent with this effect being related to inhibition of BCR-ABL kinase activity. Nilotinib or imatinib treatment did not alter STAT5 or AKT kinase activity in CML CD34 þ cells in the presence of GFs. In contrast, significant inhibition of MAPK, AKT and STAT5 activity was seen when cells were exposed to nilotinib or imatinib in GF-free conditions. These results indicate that BCR-ABL kinase inhibition by nilotinib and imatinib leads to reduced BCR-ABL-induced PI-3K/ AKT, STAT5 and MAPK activity, but that GF-induced signaling through these pathways, which are common to BCR-ABL and GF-induced signaling, is maintained in inhibitor-treated cells. Increased GF-dependent MAPK signaling in nilotinib and imatinib-treated cells could represent loss of negative feedback regulatory mechanisms or a compensatory response to inhibition of other key BCR-ABL-mediated signals.
In conclusion, our results indicate that nilotinib is significantly more potent than imatinib in inhibiting BCR-ABL kinase activity in CML progenitor cells, which however does not translate into increased progenitor suppression. Nilotinib exerted only moderate effects in inducing apoptosis of CML progenitors, and inhibition of cell division was the predominant mode of action in this cell pool. Our findings are consistent with those of Jorgensen et al., 27 indicating equipotent antiproliferative and apoptosis-inducing activity of nilotinib and imatinib in CML progenitor cells. Copland et al. 22 similarly reported that dasatinib, which is an even more potent inhibitor of BCR-ABL kinase activity, is not more effective in targeting primitive quiescent CML cells. Therefore, inhibition of BCR-ABL kinase activity by itself may not be sufficient to eliminate CML progenitors. We show that important signaling mechanisms downstream of BCR-ABL, including the MAPK, PI-3K and STAT5 pathways, continue to be active despite kinase inhibition by nilotinib, through activation of these mechanisms by exogenous GFs, bypassing the effects of inhibition of BCR-ABL kinase activity. Kinase-independent interactions of the BCR-ABL protein could also contribute to persistence of primitive hematopoietic cells despite effective kinase inhibition by nilotinib. 28 These observations suggest that additional interventions in addition to inhibition of the BCR-ABL kinase will be required to effectively induce apoptosis and eliminate CML progenitor cells.
